Resveratrol as a novel anti-herpes simplex virus nutraceutical agent: An overview

Viruses

Volumn 10, Issue 9, 2018, Pages

  Annunziata, Giuseppe ^a   Maisto, Maria ^a   Schisano, Connie ^a   Ciampaglia, Roberto ^a   Narciso, Viviana ^a   Tenore, Gian Carlo ^a   Novellino, Ettore ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Herpes simplex virus; HSV 1; HSV 2; Nutraceutical; Polyphenols; Resveratrol

Indexed keywords

ACICLOVIR; ALPHA VINIFERIN; BEHENYL ALCOHOL; DAVIDOL A; HEMSLEYANOL D; HOPEAPHENOL A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; NEOISOHOPEAPHENOL A; NUTRACEUTICAL; PAUCIFLOROL B; PAUCIFLOROL C; POLYPHENOL; PROTEIN C; QUERCETIN; REACTIVE OXYGEN METABOLITE; RESVERATROL; SIRTUIN 1; STILBENE; STILBENE DERIVATIVE; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR; UNCLASSIFIED DRUG; VATICAFFINOL; VATICAHAINOL D; VATICANOL E; VIRAL PROTEIN; ANTIVIRUS AGENT;

AMPK SIGNALING; ANTIVIRAL ACTIVITY; ANTIVIRAL SUSCEPTIBILITY; DNA SYNTHESIS INHIBITION; DOWN REGULATION; DRUG MECHANISM; GENE ACTIVATION; GENE EXPRESSION; HERPES SIMPLEX VIRUS; HERPES SIMPLEX VIRUS 2; HERPES VIRUS INFECTION; HUMAN; HUMAN ALPHAHERPESVIRUS 1; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; REVIEW; SKIN DEFECT; VIRUS REPLICATION; ANIMAL; DIETARY SUPPLEMENT; DISEASE MODEL; DRUG EFFECT; HERPES SIMPLEX; SIMPLEXVIRUS; TREATMENT OUTCOME;

ANIMALS; ANTIVIRAL AGENTS; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; HERPES SIMPLEX; HUMANS; SIMPLEXVIRUS; STILBENES; TREATMENT OUTCOME;

EID: 85053208970     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v10090473     Document Type: Review

References (48)

1. Suzich, J.B.; Cliffe, A.R. Strength in diversity: Understanding the pathways to herpes simplex virus reactivation. Virology 2018, 522, 81–91. [CrossRef] [PubMed]
2. World Health Organization. WHO Guidelines for the Treatment of Genital Herpes Simplex Virus; World Health Organization: Geneva, Switzerland, 2016.
3. James, S.H.; Prichard, M.N. Current and future therapies for herpes simplex virus infections: Mechanism of action and drug resistance. Curr. Opin. Virol. 2014, 8, 54–61. [CrossRef] [PubMed]
4. Vashishtha, A.K.; Kuchta, R.D. Effects of Acyclovir, Foscarnet, and Ribonucleotides on Herpes Simplex Virus-1 DNA Polymerase: Mechanistic Insights and a Novel Mechanism for Preventing Stable Incorporation of Ribonucleotides into DNA. Biochemistry 2016, 55, 1168–1177. [CrossRef] [PubMed]
5. Bostanghadiri, N.; Pormohammad, A.; Chirani, A.S.; Pouriran, R.; Erfanimanesh, S.; Hashemi, A. Comprehensive review on the antimicrobial potency of the plant polyphenol Resveratrol. Biomed. Pharmacother. 2017, 95, 1588–1595. [CrossRef] [PubMed]
6. Konowalchuk, J.; Speirs, J.I. Virus inactivation by grapes and wines. Appl. Environ. Microbiol. 1976, 32, 757–763. [PubMed]
7. Takaoka, M. Resveratrol, a new phenolic compound, from Veratrum grandiflorum. Nippon Kagaku Kaishi 1939, 60, 1090–1100. [CrossRef]
8. Catalgol, B.; Batirel, S.; Taga, Y.; Ozer, N.K. Resveratrol: French paradox revisited. Front. Pharmacol. 2012, 3, 141. [CrossRef] [PubMed]
9. McGill, M.R.; Du, K.; Weemhoff, J.L.; Jaeschke, H. Critical review of resveratrol in xenobiotic-induced hepatotoxicity. Food Chem. Toxicol. 2015, 86, 309–318. [CrossRef] [PubMed]
10. Trela, B.C.; Waterhouse, A.L. Resveratrol: Isomeric molar absorptivities and stability. J. Agric. Food Chem. 1996, 44, 1253–1257. [CrossRef]
11. Gambini, J.; Inglés, M.; Olaso, G.; Lopez-Grueso, R.; Bonet-Costa, V.; Gimeno-Mallench, L.; Mas-Bargues, C.; Abdelaziz, K.M.; Gomez-Cabrera, M.C.; Vina, J.; et al. Properties of Resveratrol: In Vitro and In Vivo Studies about Metabolism, Bioavailability, and Biological Effects in Animal Models and Humans. Oxid. Med. Cell. Longev. 2015, 2015, 837042. [CrossRef] [PubMed]
12. Li, C.; Xu, X.; Tao, Z.; Sun, C.; Pan, Y. Resveratrol derivatives: An updated patent review (2012–2015). Expert Opin. Ther. Pat. 2016, 26, 1189–1200. [CrossRef] [PubMed]
13. Adrian, M.; Jeandet, P.; Veneau, J.; Weston, L.A.; Bessis, R. Biological activity of resveratrol, a stilbenic compound from grapevines, against Botrytis cinerea, the causal agent for gray mold. J. Chem. Ecol. 1997, 23, 1689–1702. [CrossRef]
14. Jeandet, P.; Douillet-Breuil, A.C.; Bessis, R.; Debord, S.; Sbaghi, M.; Adrian, M. Phytoalexins from the Vitaceae: Biosynthesis, phytoalexin gene expression in transgenic plants, antifungal activity, and metabolism. J. Agric. Food Chem. 2002, 50, 2731–2741. [CrossRef] [PubMed]
15. Baur, J.A.; Sinclair, D.A. Therapeutic potential of resveratrol: The in vivo evidence. Nat. Rev. Drug Discov. 2006, 5, 493–506. [CrossRef] [PubMed]
16. Lopez, M.S.; Dempsey, R.J.; Vemuganti, R. Resveratrol neuroprotection in stroke and traumatic CNS injury. Neurochem. Int. 2015, 89, 75–82. [CrossRef] [PubMed]
17. Lançon, A.; Frazzi, R.; Latruffe, N. Anti-Oxidant, Anti-Inflammatory and Anti-Angiogenic Properties of Resveratrol in Ocular Diseases. Molecules 2016, 21, 304. [CrossRef] [PubMed]
18. Garvin, S.; Ollinger, K.; Dabrosin, C. Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenografts in vivo. Cancer Lett. 2006, 231, 113–122. [CrossRef] [PubMed]
19. Bhardwaj, A.; Sethi, G.; Vadhan-Raj, S.; Bueso-Ramos, C.; Takada, Y.; Gaur, U.; Nair, A.S.; Shishodia, S.; Aggarwal, B.B. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood 2007, 109, 2293–2302. [CrossRef] [PubMed]
20. Kotha, A.; Sekharam, M.; Cilenti, L.; Siddiquee, K.; Khaled, A.; Zervos, A.S.; Carter, B.; Turkson, J.; Jove, R. Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein. Mol. Cancer Ther. 2006, 5, 621–629. [CrossRef] [PubMed]
21. Notas, G.; Nifli, A.P.; Kampa, M.; Vercauteren, J.; Kouroumalis, E.; Castanas, E. Resveratrol exerts its antiproliferative effect on HepG2 hepatocellular carcinoma cells, by inducing cell cycle arrest, and NOS activation. Biochim. Biophys. Acta 2006, 1760, 1657–1666. [CrossRef] [PubMed]
22. Berardi, V.; Ricci, F.; Castelli, M.; Galati, G.; Risuleo, G. Resveratrol exhibits a strong cytotoxic activity in cultured cells and has an antiviral action against polyomavirus: Potential clinical use. J. Exp. Clin. Cancer Res. 2009, 28, 96. [CrossRef] [PubMed]
23. Chan, C.N.; Trinité, B.; Levy, D.N. Potent Inhibition of HIV-1 Replication in Resting CD4 T Cells by Resveratrol and Pterostilbene. Antimicrob. Agents Chemother. 2017, 61, e00408-17. [CrossRef] [PubMed]
24. Docherty, J.J.; Smith, J.S.; Fu, M.M.; Stoner, T.; Booth, T. Effect of topically applied resveratrol on cutaneous herpes simplex virus infections in hairless mice. Antivir. Res. 2004, 61, 19–26. [CrossRef] [PubMed]
25. Docherty, J.J.; Fu, M.M.; Hah, J.M.; Sweet, T.J.; Faith, S.A.; Booth, T. Effect of resveratrol on herpes simplex virus vaginal infection in the mouse. Antivir. Res. 2005, 67, 155–162. [CrossRef] [PubMed]
26. Chuanasa, T.; Phromjai, J.; Lipipun, V.; Likhitwitayawuid, K.; Suzuki, M.; Pramyothin, P.; Hattori, M.; Shiraki, K. Anti-herpes simplex virus (HSV-1) activity of oxyresveratrol derived from Thai medicinal plant: Mechanism of action and therapeutic efficacy on cutaneous HSV-1 infection in mice. Antivir. Res. 2008, 80, 62–70. [CrossRef] [PubMed]
27. Docherty, J.J.; Fu, M.M.; Stiffler, B.S.; Limperos, R.J.; Pokabla, C.M.; DeLucia, A.L. Resveratrol inhibition of herpes simplex virus replication. Antivir. Res. 1999, 43, 145–155. [CrossRef]
28. Faith, S.A.; Sweet, T.J.; Bailey, E.; Booth, T.; Docherty, J.J. Resveratrol suppresses nuclear factor-kappa B in herpes simplex virus infected cells. Antivir. Res. 2006, 72, 242–251. [CrossRef] [PubMed]
29. Leyton, L.; Hott, M.; Acuña, F.; Caroca, J.; Nuñez, M.; Martin, C.; Zambrano, A.; Concha, M.I.; Otth, C. Nutraceutical activators of AMPK/Sirt1 axis inhibit viral production and protect neurons from neurodegenerative events triggered during HSV-1 infection. Virus Res. 2015, 205, 63–72. [CrossRef] [PubMed]
30. Chen, X.; Qiao, H.; Liu, T.; Yang, Z.; Xu, L.; Xu, Y.; Ge, H.M.; Tan, R.X.; Li, E. Inhibition of herpes simplex virus infection by oligomeric stilbenoids through ROS generation. Antivir. Res. 2012, 95, 30–36. [CrossRef] [PubMed]
31. Margolis, D.M.; Rabson, A.B.; Straus, S.E.; Ostrove, J.M. Transactivation of the HIV-1 LTR by HSV-1 immediate-early genes. Virology 1992, 186, 788–791. [CrossRef]
32. Patel, A.; Hanson, J.; McLean, T.I.; Olgiate, J.; Hilton, M.; Miller, W.E.; Bachenheimer, S.L. Herpes simplex type 1 induction of persistent NF-kappa B nuclear translocation increases the efficiency of virus replication. Virology 1998, 247, 212–222. [CrossRef] [PubMed]
33. Amici, C.; Rossi, A.; Costanzo, A.; Ciafrè, S.; Marinari, B.; Balsamo, M.; Levrero, M.; Santoro, M.G. Herpes simplex virus disrupts NF-kappaB regulation by blocking its recruitment on the IkappaBalpha promoter and directing the factor on viral genes. J. Biol. Chem. 2006, 281, 7110–7117. [CrossRef] [PubMed]
34. Martin, C.; Leyton, L.; Arancibia, Y.; Cuevas, A.; Zambrano, A.; Concha, M.I.; Otth, C. Modulation of the AMPK/Sirt1 axis during neuronal infection by herpes simplex virus type 1. J. Alzheimer’s Dis. 2014, 42, 301–312. [CrossRef] [PubMed]
35. Salminen, A.; Hyttinen, J.M.; Kaarniranta, K. AMP-activated protein kinase inhibits NF-κB signaling and inflammation: Impact on healthspan and lifespan. J. Mol. Med. 2011, 89, 667–676. [CrossRef] [PubMed]
36. Gonzalez-Dosal, R.; Horan, K.A.; Rahbek, S.H.; Ichijo, H.; Chen, Z.J.; Mieyal, J.J.; Hartmann, R.; Paludan, S.R. HSV infection induces production of ROS, which potentiate signaling from pattern recognition receptors: Role for S-glutathionylation of TRAF3 and 6. PLoS Pathog. 2011, 7, e1002250. [CrossRef] [PubMed]
37. Gonzalez-Dosal, R.; Horan, K.A.; Paludan, S.R. Mitochondria-derived reactive oxygen species negatively regulates immune innate signaling pathways triggered by a DNA virus, but not by an RNA virus. Biochem. Biophys. Res. Commun. 2012, 418, 806–810. [CrossRef] [PubMed]
38. Hu, J.; Li, H.; Luo, X.; Li, Y.; Bode, A.; Cao, Y. The role of oxidative stress in EBV lytic reactivation, radioresistance and the potential preventive and therapeutic implications. Int. J. Cancer 2017, 141, 1722–1729. [CrossRef] [PubMed]
39. Zhuang, W.; Wang, C.; Shi, X.; Qiu, S.; Zhang, S.; Xu, B.; Chen, M.; Jiang, W.; Dong, H.; Qiao, Y. MCMV triggers ROS/NLRP3-associated inflammasome activation in the inner ear of mice and cultured spiral ganglion neurons, contributing to sensorineural hearing loss. Int. J. Mol. Med. 2018, 41, 3448–3456. [CrossRef] [PubMed]
40. Tal, M.C.; Sasai, M.; Lee, H.K.; Yordy, B.; Shadel, G.S.; Iwasaki, A. Absence of autophagy results in reactive oxygen species-dependent amplification of RLR signaling. Proc. Natl. Acad. Sci. USA 2009, 106, 2770–2775. [CrossRef] [PubMed]
41. Matsuzawa, A.; Saegusa, K.; Noguchi, T.; Sadamitsu, C.; Nishitoh, H.; Nagai, S.; Koyasu, S.; Matsumoto, K.; Takeda, K.; Ichijo, H. ROS-dependent activation of the TRAF6-ASK1-p38 pathway is selectively required for TLR4-mediated innate immunity. Nat. Immunol. 2005, 6, 587–592. [CrossRef] [PubMed]
42. Mogensen, T.H.; Melchjorsen, J.; Hollsberg, P.; Paludan, S.R. Activation of NF-κB in virus-infected macrophages is dependent on mitochondrial oxidative stress and intracellular calcium: Downstream involvement of the kinases TGF-beta-activated kinase 1, mitogen-activated kinase/extracellular signal-regulated kinase kinase 1, and I kappa B kinase. J. Immunol. 2003, 170, 6224–6233. [PubMed]
43. Tian, J.; Avalos, A.M.; Mao, S.Y.; Chen, B.; Senthil, K.; Wu, H.; Parroche, P.; Drabic, S.; Golenbock, D.; Sirois, C.; et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat. Immunol. 2007, 8, 487. [CrossRef] [PubMed]
44. Chiang, E.; Dang, O.; Anderson, K.; Matsuzawa, A.; Ichijo, H.; David, M. Cutting edge: Apoptosis-regulating signal kinase 1 is required for reactive oxygen species-mediated activation of IFN regulatory factor 3 by. lipopolysaccharide. J. Immunol. 2006, 176, 5720–5724. [CrossRef] [PubMed]
45. Dostert, C.; Petrilli, V.; van Bruggen, R.; Steele, C.; Mossman, B.T.; Tschopp, J. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 2008, 320, 674–677. [CrossRef] [PubMed]
46. Cho, Y.S.; Challa, S.; Moquin, D.; Genga, R.; Ray, T.D.; Guildford, M.; Chan, F.K. Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell 2009, 137, 1112–1123. [CrossRef] [PubMed]
47. Eghbaliferiz, S.; Iranshahi, M. Prooxidant Activity of Polyphenols, Flavonoids, Anthocyanins and Carotenoids: Updated Review of Mechanisms and Catalyzing Metals. Phytother. Res. 2016, 30, 1379–1391. [CrossRef] [PubMed]
48. Likhitwitayawuid, K.; Sritularak, B.; Benchanak, K.; Lipipun, V.; Mathew, J.; Schinazi, R.F. Phenolics with antiviral activity from Millettia erythrocalyx and Artocarpus lakoocha. Nat. Prod. Res. 2005, 19, 177–182. [CrossRef] [PubMed]